A Randomized, Multicenter, Double-blind, Placebo-controlled, 3 × 3 Factorial Design, Phase II Study to Evaluate the Efficacy and Safety of the Combination of Fimasartan/Amlodipine in Patients With Essential Hypertension-Reference-Cited by-同舟云学术

A Randomized, Multicenter, Double-blind, Placebo-controlled, 3 × 3 Factorial Design, Phase II Study to Evaluate the Efficacy and Safety of the Combination of Fimasartan/Amlodipine in Patients With Essential Hypertension

Published:2015-11 Issue:11 Volume:37 Page:2581-2596.e3
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Lee Hae-Young,Kim Yong-Jin,Ahn Taehoon,Youn Ho-Joong,Chull Chae Shung,Seog Seo Hong,Kim Ki-Sik,Rhee Moo-Yong,Choi Dong-Ju,Kim Jae-Joong,Chun Kook-Jin,Yoo Byung-Su,Park Jong-Seon,Oh Seok-Kyu,Kim Dong-Soo,Kwan Jun,Ahn Youngkeun,Bae Park Jeong,Jeong Jin-ok,Hyon Min-Soo,Cho Eun-Joo,Han Kyoo-Rok,Kim Doo-Il,Joo Seung-Jae,Shin Jin-Ho,Sung Ki-Chul,Jeon Eun-Seok

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference27 articles.

1. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC);Mancia;J Hypertens,2013

2. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial;Julius;Lancet,2004

3. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients;Jamerson;N Engl J Med,2008

4. Efficacy and Tolerability of Fimasartan, a New Angiotensin Receptor Blocker, Compared With Losartan (50/100 mg): A 12-Week, Phase III, Multicenter, Prospective, Randomized, Double-Blind, Parallel-Group, Dose Escalation Clinical Trial With an Optional 12-Week Extension Phase in Adult Korean Patients With Mild-to-Moderate Hypertension

5. Efficacy and safety of 30-mg fimasartan for the treatment of patients with mild to moderate hypertension: an 8-week, multicenter, randomized, double-blind, phase III clinical study;Youn;Clin Ther,2014

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Personalized Antihypertensive Treatment Optimization With Smartphone‐Enabled Remote Precision Dosing of Amlodipine During the COVID‐19 Pandemic (PERSONAL‐CovidBP Trial);Journal of the American Heart Association;2024-02-20

2. Blood Pressure–lowering Effect of Fimasartan Versus Comparators: A Cross-inference With a Systematic Review and Meta-analysis Through a Quality-management System;Clinical Therapeutics;2023-05

3. A randomized, double-blind, multicenter, phase III study on the efficacy and safety of a combination treatment involving fimasartan, amlodipine, rosuvastatin in patients with essential hypertension and dyslipidemia who fail to respond adequately to fimasartan monotherapy;Clinical Hypertension;2022-12-01

4. Newer Angiotensin Receptor Blockers;Hypertension and Cardiovascular Disease in Asia;2022

5. Systematic Review with Network Meta-Analysis: Comparative Efficacy and Safety of Combination Therapy with Angiotensin II Receptor Blockers and Amlodipine in Asian Hypertensive Patients;International Journal of Hypertension;2019-11-11